Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors
Avtorji:ID Zwitter, Matjaž (Avtor)
ID Rossi, Antonio (Avtor)
ID Di Maio, Massimo (Avtor)
ID Pohar Perme, Maja (Avtor)
ID Lopes, Gilberto (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.degruyter.com/view/j/raon.2017.51.issue-3/issue-files/raon.2017.51.issue-3.xml
 
.pdf PDF - Predstavitvena datoteka, prenos (552,79 KB)
MD5: 45794E5FFDE1B313B706C01B3321D381
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. Methods. Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson%s correlation coefficient and the coefficient of determination, separately for first-line and second-line setting. Results. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with nonsquamous carcinoma (in first-line setting), proportion of never-smokers (both in first- and second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- and second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR%mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months. Conclusions. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR%mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted.
Ključne besede:lung cancer, NSCLC, intercalated treatment, EGFR, tyrosine -kinase inhibitors
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.09.2017
Založnik:Association of Radiology and Oncology
Leto izida:2017
Št. strani:str. 241-251, I
Številčenje:Vol. 51, No. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19017 Novo okno
UDK:616-006
ISSN pri članku:1318-2099
DOI:10.1515/raon-2017-0029 Novo okno
COBISS.SI-ID:2780283 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:31.05.2024
Število ogledov:102
Število prenosov:94
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Nazaj